The US pharmaceutical company Pfizer announced on Tuesday that it expects to bill about $ 15 billion in 2021 for its vaccine against the coronavirus COVID-19 developed in collaboration with BioNTech. which represents about 25% of your business forecast.
Pfizer, which reported its quarterly and cumulative results this morning, noted that its total billing forecasts are between $ 59,400 and $ 61,400 million for the full fiscal year, a figure that reflects the countries’ gradual vaccination and their economic recovery.
In 2020 the company made a profit of $ 9,616 million, 41% less than last year, while revenues were up a slight 2% to 41,908 million, mainly due to sales of its oncology and internal medicine products.
“Our ability to act quickly and use advanced science to address the world’s greatest medical challenges was tested by the COVID-19 pandemic. Our record-breaking success in developing a vaccine, together with our partner BioNTech is an example of what this new Pfizer is capable of, ”said CEO, Albert Bourla.
Two months ago, the COVID-19 vaccine developed by Pfizer and BioNTech was the first in the world to be approved for emergency use by authorities, in the United Kingdom, and has now received a green light in more than 50 countries, but the problems are transferred to distribution.
Pfizer pointed out that it has agreed to deliver 200 million doses with the US government and brought forward the delivery date to “the end of May” when it previously discussed July, while in the cases of the European Union, which it has agreed to 300 million doses to be delivered, and the Covax platform, 40 million doses, did not specify the data.
The pharmaceutical company, on the other hand, reiterated that its vaccine has shown high efficacy against new variants of the virus in its experiments, which “do not indicate the need for a new vaccine,” but assured that it “is ready to respond. “. if these “prove. to escape immunity” of your preparation.
In terms of financial results, Pfizer already registered an improvement in its numbers in the fourth quarter of 2020, including the first sale of the anticovid vaccine that brought in $ 154 million.
Between October and December, the pharmaceutical company posted a profit of 594 million, reversing the 337 million losses it suffered in the same section of 2019., and had sales of 11,684 million, 12% higher year on year.
Over the quarter, Pfizer completed the 2019 merger between its Upjohn businesses and GlaxoSmithKline’s Mylan firm, creating a new generic drug company called Viatris.
For the year, half of its sales were in oncology products (nearly $ 11 billion, up 21%) and internal medicine (9 billion, up 2%).
Pfizer’s vaccine division brought in about 6.5 billion (2% more) and the division with the highest prognosis was that of rare diseases, which grew by 29% to nearly three billion.
Pfizer raised its earnings per share forecast for 2021 “primarily as a result of further refinements to the COVID-19 vaccine billing forecast” to a range of $ 3.10 to $ 3.20, up from $ 3 to $ 3 , 10 which it announced until mid-January.
Results were mixed on Wall Street, with stocks falling about 3% at the start of the session. In the past year they have lost 3% of their value.
OA
